Medical School News and Research

RSS

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Yoga can help prevent mental health problems in high-school students

Yoga classes have positive psychological effects for high-school students, according to a pilot study in the April Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics

5 Apr 2012

Ultrasound & MRI as additions to mammograms for breast cancer detection

A new study shows that annual mammogram screenings, combined with ultrasounds and MRIs, significantly increase the detection of cancer in women who had an elevated risk of breast cancer.

4 Apr 2012

Impact of Personal Genomics Study to launch data collection phase

As genetic risk information plays an increasingly important role in the diagnosis and treatment of many diseases, private companies have made personal genomic testing for these risk factors widely available to the public. However, very little data has been gathered to understand the motivations and expectations of consumers of personal genomic services, the psychological and behavioral impact of these services, and the associated ethical, legal and social issues—until now.

4 Apr 2012

Study: Functional link between two major causes of treatment failure in breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows a functional link between two major causes of treatment failure in breast cancer, showing the protein behind one of these causes plays a role in increasing the drug resistance properties of the other.

4 Apr 2012

OvaScience completes $37M Series B financing

OvaScience, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, today announced that it has completed a $37 million Series B financing.

4 Apr 2012

Brains of people with anorexia and obesity are wired differently

The brains of people with anorexia and obesity are wired differently, according to new research. Neuroscientists for the first time have found that how our brains respond to food differs across a spectrum of eating behaviors - from extreme overeating to food deprivation.

4 Apr 2012

Infections in older adults may increase risk of hospitalization for dangerous blood clots

Research shows older adults who get infections of any kind - such as urinary, skin, or respiratory tract infections - are nearly three times more likely to be hospitalized for a dangerous blood clot in their deep veins or lungs, University of Michigan Health System research shows.

4 Apr 2012

Viewpoints: Shouldering the health costs of the 'irresponsible'; Learning from the parallels between Obamacare and the 'war on terror'

The central idea of the Patient Protection and Affordable Care Act -; the formal name of the Obamacare law -; emphasized in the hearings is to spread the cost of health care to ever-larger pools of Americans. In particular, to those who pay low health insurance premiums, the young who choose to have no insurance and the healthy.

4 Apr 2012

UCM to launch Medicine and Religion Faculty Scholars Program

Is a doctor's spirituality an obstacle or a benefit in the clinic? Does religious affiliation affect medical decision making? Can a spiritual calling protect doctors against career burnout? With a $2.5 million grant from the John Templeton Foundation, the University of Chicago Medicine will launch a new program to help faculty scholars study these questions and more about the role of spirituality in medical practice and education.

3 Apr 2012

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.

3 Apr 2012

Combination treatment effective against melanoma

Research from The Cancer Institute of New Jersey (CINJ) shows that a coordinated effort to block signaling pathways that promote cancer cell growth and survival enhances programmed cell death in melanoma.

3 Apr 2012

Expensive robotic-assisted bladder cancer surgery results in fewer deaths, in-patient complications

With technological advancements opening the door to less invasive medical procedures, robotic-assisted surgery is becoming increasingly popular, despite being more expensive than traditional surgery. Robotic-assisted surgical removal of the bladder due to cancer is a new approach to the traditional "open" - or more invasive - operation called a radical cystectomy.

3 Apr 2012

Mammograms may increase risk for ‘over-diagnosis’ of cancers: Study

According to a new study from Norway up to a fourth of breast cancers found through mammograms are harmless and would not cause noticeable disease during the women's lifetimes. Such women are said to be over-diagnosed, because their cancers would not have caused symptoms or death. Over-diagnosis is a problem because women may receive tests and treatment they did not actually need.

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

Study shows how fat cells can protect the body against diabetes

In a finding that may challenge popular notions of body fat and health, researchers at Beth Israel Deaconess Medical Center (BIDMC) have shown how fat cells can protect the body against diabetes. The results may lead to a new therapeutic strategy for preventing and treating type 2 diabetes and obesity-related metabolic diseases, the authors say.

2 Apr 2012

Brain images show nerves ‘crisscrossing’ in neat but complex patterns: Study

New images of the brain reveal a deceptively simple pattern of organization in the wiring of this complex organ. Instead of nerve fibers travelling randomly through the brain like spaghetti, as some imaging has suggested, the new portraits reveal two-dimensional sheets of parallel fibers ‘crisscrossing’ other sheets at right angles in a grid-like structure that folds and contorts with the convolutions of the brain. This same pattern appeared in the brains of humans, rhesus monkeys, owl monkeys, marmosets and galagos, researchers report Thursday in the journal Science.

1 Apr 2012

CINJ experts available for discussion on cancer

April marks National Cancer Control Month, which focuses on the importance of prevention, treatment and research in the fight against cancer.

30 Mar 2012

ASD more prevalent among New Jersey children: CDC

New statistics issued by the Centers for Disease Control and Prevention (CDC) indicate that the prevalence of autism spectrum disorders found among 8-year-old children in a sample area of New Jersey is significantly higher than in most other states surveyed.

30 Mar 2012